Premium
The Prognostic Value of Ephrin Type‐A2 Receptor (EPHA2) and Ki67 in Renal Cell Carcinoma Patients: An Immunohistochemical and Bioinformatical Approach
Author(s) -
Talaat Iman Mamdouh,
Okap Israa Sobhy,
El Sheikh Samar Mohamed,
Youssif Tamer Mohammed Abou,
Hachim Ibrahim Yaseen,
Hachim Mahmood Yaseen
Publication year - 2019
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.2019.33.1_supplement.lb366
Subject(s) - medicine , immunohistochemistry , renal cell carcinoma , eph receptor a2 , stage (stratigraphy) , oncology , cancer , disease , receptor tyrosine kinase , ephrin , pathology , receptor , biology , paleontology
Background The incidence of renal cell carcinoma (RCC), the most common malignant renal epithelial tumour, is increasing worldwide. Patients usually present with advanced disease and mostly have unpredicted clinical behaviour. A variety of prognostic factors have been proposed as useful parameters, however many of them showed limited clinical value. Thus, the discovery of novel prognostic markers, which might help in predicting patients' outcome and additional new targets to treat this disease are still in great demand. EphA2, a receptor tyrosine kinase, was found to be overexpressed in several malignancies and its expression in different tumours was found to be associated with poor prognostic features. In addition, a group of emerging strategies was recently introduced to target this receptor and found to show anti‐tumorigenic activity in various pre‐clinical cancer models. Aim To investigate the prognostic value of EphA2 expression in RCC patients and its association with other clinicopathological parameters as well as Ki67 expression, which is a well‐known proliferative and prognostic marker. Materials and Methods The expression of EphA2 and Ki67 was investigated immunohistochemically, and the results were correlated with the different clinicopathological parameters in 50 primary tumour blocks obtained from RCC cases surgically managed in the Urology Department, Alexandria University Main Hospital, during the period (2012–2015). In addition, the association between the EphA2 mRNA expression and the tumour stage as well as the patient outcome was also evaluated using two large publicly available databases. Results Our results showed a significant association between EphA2 expression and the tumour size, the nuclear grade, the tumour stage, the patient's outcome and the Ki‐67 expression (P < 0.05 for all). The same trend was also observed with EphA2 mRNA expression using larger patients' cohorts in two publicly available databases. Notably, EphA2 protein expression showed higher levels of co‐expression with the proliferative marker Ki67. Conclusion We concluded that higher expression of EphA2 and Ki67 in tumour tissues predicts a locally aggressive behaviour and poor outcome of RCC patients. Moreover, our results give a rationale for the potential benefits of using novel therapeutic strategies with the aim of targeting EphA2 receptor in RCC that might help in improving their outcome. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .